Presymptomatic treatment of spinal muscular atrophy with risdiplam leads to improved functional outcomes
1. In this single-group trial, among infants predicted to develop type 1 spinal muscular atrophy (SMA) who were treated presymptomatically ...
1. In this single-group trial, among infants predicted to develop type 1 spinal muscular atrophy (SMA) who were treated presymptomatically ...
1. Risdiplam treatment increased the survival of motor neuron protein in the blood of infant patients diagnosed with type 1 ...
1. Intrathecal injections of nusinersen in pediatric later-onset spinal muscular atrophy (SMA) patients were associated with increased clinical motor function ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.